Relay Therapeutics reports Q1 EPS (46c), consensus (48c)

Reports Q1 revenue $7.7M vs. $10.0M in Q1 of 2024. As of March 31, 2025, cash, cash equivalents and investments totaled $710.3M, as compared to $781.3M as of December 31, 2024. The company expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2029. “2025 is a year of execution across a range of high value clinical programs,” said CEO Sanjiv Patel, M.D. “The ongoing changes to our cost base are designed to enable a full funding of key initiatives including generating topline data from the ReDiscover-2 trial and clinical proof-of-concept data in vascular malformations.”